SuperHERO: A Phase II Trial Evaluating Radiotherapy Omission for Low-risk HER2-positive Breast Cancer
The purpose of this study is to find out whether it is safe to skip (omit) radiation therapy to the breast after lumpectomy in people with low-risk HER2-positive breast cancer who are receiving HER2-targeted therapy.
⁃ A patient cannot be considered eligible for this study unless ALL of the following conditions are met. Please contact the study PI for exceptions, or if uncertainties arise.
• The trial is open to female and male patients who have undergone breast conserving surgery and have received neoadjuvant\* or adjuvant systemic therapy with a HER2-targeted therapeutic regimen.
• The maximum window between surgery (neoadjuvant cohort) or last chemotherapy (adjuvant cohort) and enrollment is 90 days.
• While the standard duration of neoadjuvant or adjuvant systemic therapy is at least 12 weeks, patients will be eligible if they receive a minimum of 8 weeks of systemic therapy. Patients treated with an antibody-drug conjugate (ADC; eg. T-DM1 or T-DXd) must have received at least 6 cycles of this treatment.
• \*For the neoadjuvant cohort: Patients are eligible if they achieved pCR with HER2-targeted preoperative treatment. Pathologic complete response is defined as ypT0/TisN0 based on surgical pathology. Patients treated with and ADC must have received at least 6 cycles of this treatment.
• The patient must be ≥18 years of age.
• The patient must have an ECOG performance status of 0, 1, or 2/Karnofsky performance status above 60.
• Histologically or cytologically confirmed invasive breast carcinoma.
• The tumor must have been determined to be HER2-positive by current ASCO/CAP guidelines based on local testing results.
• The tumor must have ER and PgR status assessed.
• The following staging criteria must be met according to AJCC 8th edition criteria:
⁃ Adjuvant cohort
• Following resection, the patient's primary tumor must be ≤ 3 cm.
• Surgical axillary evaluation via sentinel node biopsy or axillary dissection
• Surgical lumpectomy margins must be negative for invasive cancer and ductal carcinoma in situ (no ink on tumor).
⁃ Neoadjuvant cohort:
• Prior to neoadjuvant therapy, the patient's primary tumor must be \<5 cm by imaging studies with negative axillary nodes (cN0) based on axillary U/S, CT, PET or MRI. Physical examination alone is not sufficient documentation of cN0 status.
• The patient must have undergone surgical axillary nodal evaluation demonstrating ypN0 (eg. axillary node dissection, sentinel node biopsy with at least 3 sentinel lymph nodes removed, or sentinel node biopsy followed by axillary node dissection).
• Must be ypT0/TisN0 at surgery (lumpectomy); patients with residual non invasive disease (DCIS) in the surgical specimen (ypTis), are only eligible if residual DCIS spans ≤1 cm, and surgical margins are negative for DCIS.
• Bilateral mammogram or MRI within 52 weeks prior to enrollment.